Cool and emerging new concepts to watch out for in Gliomas
Rotterdam harbour where even the architecture can look like CAR-T cell constructs!
For decades four tumour types always seemed to be considered the ‘graveyard’ of drug development with many a promising therapy hitting the skids and being banished to dog drug heaven…
- Metastatic melanoma
- Small cell lung cancer (SCLC)
- Acute myeloid leukemia (AML)
- Glioblastoma (GBM)
Of these, melanoma has been dramatically transformed by targeted therapies and checkpoint blockade, while AML has come of age with novel targeted therapies being approved for specific subsets and many more in development, and even SCLC has seen some success with both immunotherapy and targeted approaches.
This leaves us with refractory GBM as the main holdout and a 5% survival rate at five years post diagnosis.
The good news is there are various novel approaches coming through the clinic and more in preclinical development, some of which might well move the survival needle if all goes well.
In order to see improved success in the clinic though, we first have to marry the novel ideas with a greater understanding of the inherent challenges and hurdles we wish to address. There are plenty of smart and articulate people quietly working at the coal face in various brain tumours with some intriguing ideas being evaluated going beyond the obvious.
In our latest BSB interview we talk to one of the experts in this niche and discuss the challenges, opportunities, and importantly – where is the field moving towards…
To continue reading our latest highlights on oncology new product development, including an expert interview plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
